Close Menu

    Subscribe to Updates

    Get the latest creative news from Healthradar about News,Health and Gadgets.

    Bitte aktiviere JavaScript in deinem Browser, um dieses Formular fertigzustellen.
    Wird geladen
    What's Hot

    Cleveland Clinic and Dyania Health Partner to Accelerate Clinical Trial Recruitment with AI

    28. August 2025

    Rimidi Partners with Beth Israel Deaconess Medical Center on Food as Medicine Trial

    28. August 2025

    FDA approves updated covid vaccines, but with severe new limits

    28. August 2025
    Facebook X (Twitter) Instagram
    Facebook X (Twitter) Instagram Pinterest Vimeo
    healthradar.nethealthradar.net
    • Home
    • Ai
    • Gadgets
    • Health
    • News
    • Contact Us
    Contact
    healthradar.nethealthradar.net
    Home»News»Quest to offer Fujirebio’s FDA-cleared Alzheimer’s blood test
    News

    Quest to offer Fujirebio’s FDA-cleared Alzheimer’s blood test

    HealthradarBy Healthradar15. Juli 2025Keine Kommentare3 Mins Read
    Share Facebook Twitter Pinterest LinkedIn Tumblr Reddit Telegram Email
    Quest to offer Fujirebio’s FDA-cleared Alzheimer’s blood test
    Share
    Facebook Twitter LinkedIn Pinterest Email


    Dive Brief:

    • Quest Diagnostics is planning to offer laboratory testing based on Fujirebio Diagnostics’ recently Food and Drug Administration-authorized Alzheimer’s disease blood test.
    • In May, Fujirebio’s in vitro diagnostic became the first blood test to aid in the diagnosis of Alzheimer’s cleared by the FDA. Quest, which disclosed its plans for the IVD last week, launched a laboratory-developed test for similar biomarkers in April.
    • The clinical lab plans to make Fujirebio’s Lumipulse G pTau 217/β-Amyloid 1-42 Plasma Ratio test available for use by physicians and researchers this summer.

    Dive Insight:

    Fujirebio’s IVD compares the ratio of two proteins, pTau217 and beta-amyloid 1-42, to help identify patients with amyloid pathology associated with Alzheimer’s. Cerebrospinal fluid tests that analyze the same biomarkers are an established part of the toolkit for assessing patients with cognitive impairment. However, the tests need samples that are collected via lumbar puncture.

    Blood tests could be more accessible and scalable than CSF diagnostics. The advantages have spurred interest in using blood tests to identify patients who should have a PET scan to check for amyloid plaques in the brain. Ultimately, blood tests could eliminate the need for PET scans in some patients.

    Quest has been working toward that goal, launching LDTs and now positioning itself to start providing Fujirebio’s FDA-cleared diagnostic. Fujirebio validated the test in a study of 499 people, linking the IVD to positive and negative predictive values of 92% and 97%, respectively. Less than 20% of people received indeterminate results.

    The predictive values are higher than those Quest reported for its beta-amyloid 42/40 and pTau217 LDT in April. Quest CEO Jim Davis discussed the company’s test at a William Blair event in June, telling attendees that “it over time will largely replace PET-CT as the primary diagnostic tool for the detection of Alzheimer’s.”

    Davis said testing for a combination of beta-amyloid and tau biomarkers could “give clinicians an earlier view of early onset Alzheimer’s long before you would see it in a PET-CT.” The value of early diagnosis is increasing as companies develop medicines that are most effective in people in the early stages of the disease. Davis said uptake of Quest’s LDT was “really starting to take off.”

    “Primary care physicians are using this test to determine should a patient get referred to a neurologist or not. And the number one problem with Alzheimer’s disease today is getting a referral into a neurologist,” Davis said. “If a primary care physician can run a test to determine who really needs to get referred and who doesn’t, it will be a huge help to the overall health system.”



    Source link

    Alzheimers blood FDAcleared Fujirebios offer Quest Test
    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
    Previous ArticleAI’s Rapid Ascent in Healthcare Amidst Clinician Pressures
    Next Article Teladoc Health Launches Wellbound Employee Assistance Program –
    ekass777x
    Healthradar
    • Website

    Related Posts

    News

    Rimidi Partners with Beth Israel Deaconess Medical Center on Food as Medicine Trial

    28. August 2025
    News

    Healthcare C-Suite Acknowledges AI Potential but Lacks Trust

    28. August 2025
    News

    mPulse Acquires Clarity Software Solutions to Redefine Health Communications

    27. August 2025
    Add A Comment
    Leave A Reply Cancel Reply

    Top Posts

    Garmin Venu 4: Everything we know so far about the premium smartwatch

    7. August 202552 Views

    The Top 3 Tax Mistakes High-Earning Physicians Make

    7. August 202522 Views

    Linea Expands AI-Powered Heart Failure Care Solution

    6. August 202519 Views

    Neurode wants to treat and track ADHD symptoms through a wearable headband

    1. Juni 20259 Views
    Stay In Touch
    • Facebook
    • YouTube
    • TikTok
    • WhatsApp
    • Twitter
    • Instagram
    Latest Reviews

    Subscribe to Updates

    Bitte aktiviere JavaScript in deinem Browser, um dieses Formular fertigzustellen.
    Wird geladen
    About Us

    Welcome to HealthRadar.net — your trusted destination for discovering the latest innovations in digital health. We are dedicated to connecting individuals, healthcare professionals, and organizations with cutting-edge tools, applications

    Most Popular

    Garmin Venu 4: Everything we know so far about the premium smartwatch

    7. August 202552 Views

    The Top 3 Tax Mistakes High-Earning Physicians Make

    7. August 202522 Views
    USEFULL LINK
    • About Us
    • Contact Us
    • Disclaimer
    • Privacy Policy
    QUICK LINKS
    • Ai
    • Gadgets
    • Health
    • News
    • About Us
    • Contact Us
    • Disclaimer
    • Privacy Policy
    Copyright© 2025 Healthradar All Rights Reserved.

    Type above and press Enter to search. Press Esc to cancel.